作者
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, Mehmet Artaç, Nail Özhan, Emre Akar, Burcu Çakar, Osman Köstek, Meltem Ekenel, Mustafa Erman, Hasan Şenol Coşkun, Fatih Selçukbiricik, Özge Keskin, Fatma Paksoy Türköz, Kerem Oruç, Selami Bayram, Uğur Yılmaz, İrem Bilgetekin, Birol Yıldız, Mehmet Ali Nahit Şendur, Nail Paksoy, Ahmet Dirican, Dilek Erdem, Meltem Selam, Özgür Tanrıverdi, Semra Paydaş, Zuhat Urakçı, Elif Atağ, Sabri Güncan, Yüksel Ürün, Ali Alkan, Ali Osman Kaya, Deniz Tataroğlu Özyükseler, Halil Taşkaynatan, Mustafa Yıldırım, Müge Sönmez, Tuğba Başoğlu, Şeyda Gündüz, Saadettin Kılıçkap
发表日期
2021/9/1
期刊
European urology focus
卷号
7
期号
5
页码范围
1061-1066
出版商
Elsevier
简介
Background
Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
Objective
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Design, setting, and participants
Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ.
Outcome measurements and statistical analysis
The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were …
学术搜索中的文章
D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan… - European urology focus, 2021